Geron Corp (GERN) income statement
GERNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 2/30
$0.99−0.01 (-0.91%)
Close on Nov 18, 2026Market cap $636.63MP/E –Yield –
Geron Corp income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -33.0%
Financial strength
- Current ratio
- 6.92
- Debt to equity
- 0.55
- Debt to assets
- 23.1%
- Cash to current liabilities
- 89.1%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.91
- Dividend yield
- –
See a number that looks wrong?